At a glance
ClinicalIndex Comparison RecordN/ACompleted· 389 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Retrospective Chart Review of Real-world Treatment Outcomes in Patients With Locally Advanced Unresectable or Metastatic Urothelial Cancer Based on HER2 Expression
In Brief
An observational study for Urothelial Carcinoma. Completed, enrolled 389 participants across 23 sites in 4 countries.
Detailed Summary
This study is being done to learn about urothelial cancers that make HER2 and how that affects treatment choices for participants with urothelial cancer. During this study, the medical and health records of participants will be reviewed to learn more about their health. Participants will have urothelial cancer that has grown in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsUrothelial Carcinoma
CountriesAustria, France, Germany, United States
Collaborators--
Timeline
N/ACompletedFinished
202420252026
First PostedJun 2023
Enrollment StartJun 2023
Primary CompletionJun 2025
TodayJul 2026
First PostedJun 15, 2023
Enrollment StartJun 29, 2023
Primary CompletionJun 18, 2025
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 3.0 years ago